NCT03925428: Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 12 Years and older (Child, Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for the dose escalation phase (not the expansion phase); Patients must have received previous therapy with at least 1 combination chemotherapy regimen for metastatic disease
Exclusions: Patients with known untreated or symptomatic brain or leptomeningeal metastases- see trial for details

Comments are closed.

Up ↑